The sun care landscape in Canada is entering a transformative phase following Health Canada’s official addition of dsm-firmenich’s Parsol Shield (bemotrizinol) to the Secondary Sunscreen Monograph. While the photostable, broad-spectrum filter has long been a staple in primary sunscreens where UV protection is the main function, this regulatory update permits its use at concentrations up to 6% in a much broader array of products. This change effectively bridges the gap between specialized beach-wear sunscreens and daily-wear cosmetics, such as multifunctional skincare and daily moisturizers, where sun protection previously played a secondary role.
This development has significant implications for formulators seeking to meet the rising consumer demand for "skintelligence" and hybrid beauty products. By allowing Parsol Shield in secondary sunscreen categories, the updated monograph provides the technical freedom to create innovative formats that do not sacrifice sensorial experience for high-performance protection. The ingredient is noted for its effortless compatibility and ability to maintain lightweight, silky textures—qualities that are essential for encouraging the daily sunscreen habits that drive public skin health.
Furthermore, the approval reinforces a strengthening global regulatory alignment, echoing dsm-firmenich’s ongoing efforts to secure FDA approval for the same active ingredient in the United States. For global manufacturers, this milestone simplifies product strategies by enabling the development of "global chassis" formulations. By reducing the need for region-specific formulations, brands can decrease complexity in their supply chains and accelerate the time to market for new products that offer consistent, rock-solid stability and broad-spectrum UVA/UVB protection across multiple borders.
